Pfizer discontinues Phase IIb of S. aureus vaccine

Pfizer Inc. (NYSE:PFE) discontinued the Phase IIb STRIVE trial of PF-06290510 to prevent postoperative invasive Staphylococcus aureus infections in patients undergoing elective spinal fusion surgery after an interim analysis by an IDMC concluded that the S. aureus vaccine composed of four antigens had a low probability of meeting the trial's primary endpoint.

Patients in the double-blind, international trial received a single intramuscular injection of PF-06290510 or placebo given 10-60 days prior to surgery and evaluated a primary endpoint of the number of patients with postoperative S. aureus blood stream infections and/or deep incisional or organ/space surgical site infections occurring within 90 days of surgery...